Compare Eni SpA (E) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Humana Inc — how do they compare? Eni SpA trades at $48.37 (market cap $70.34B), while Humana Inc trades at $395.09 (market cap $48.96B). The key difference: Eni SpA is the larger of the two by market cap, and Eni SpA pays the higher dividend (4.99%). Which is the better fit depends on your goals.
| E | HUM | |
|---|---|---|
Market Cap | $70.34B | $48.96B |
Sector | Energy | Health |
52-Week High | $57.61 | $409.42 |
52-Week Low | $32.93 | $163.67 |
Enterprise Value | $89.25B | $58.00B |
Dividend Yield | 4.99% | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $49.55, up 0.22% with a bullish technical signal supported by moving averages. The company shows stable cash flow generation with $238M net cash flow in 2025 and maintains a dividend of $0.63. Recent strategic expansions into renewable fuels, lithium, and energy trading through partnerships with BMW, Mercuria, and UKAEA highlight diversification efforts. Valuation metrics appear reasonable with P/E of 21.6 and EV/EBITDA of 3.83, though revenue has declined from $132.5B in 2022 to $82.15B in 2025.
The outlook balances strategic growth initiatives against revenue pressures. Opportunities exist in energy transition projects and trading expansion, but risks include oil price volatility and execution challenges. Analyst sentiment is mixed with 34.6% buy ratings versus 61.5% hold, suggesting cautious optimism. The stock's investment case hinges on successful diversification while managing core energy market exposure.
Humana (HUM) trades at $406.70, up 0.17% on the day, and is currently above its consensus price target. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company has beaten earnings expectations for three consecutive quarters and is executing a strategic shift from membership growth to profitability, targeting a 3% Medicare Advantage margin by 2028. Revenue has grown consistently from $92.9B in 2022 to $129.7B in 2025.
The outlook is mixed. The company's strategic pivot and recent contract wins like the Illinois Medicaid contract present growth opportunities. However, significant risks include multiple legal investigations into statements on healthcare costs, declining net profit margins (from 3.02% in 2022 to 0.91% in 2025), and a high P/E ratio of 43.52. Analyst sentiment is cautious, with a majority 'Hold' rating and a consensus price target 13% below the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
